Cellular uptake of ODNs in HIV-1 human-infected cells: A role for viral particles in DNA delivery?

Oligonucleotides

Volumn 17, Issue 2, 2007, Pages 151-165

  Métifiot, Mathieu ^a,b   Faure, Aurélie ^a,b   Guyonnet Duperat, Véronique ^c   Bellecave, Pantxika ^a,b   Litvak, Simon ^a,b   Ventura, Michel ^a,b   Andréola, Marie Line ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Institut Fédératif De Recherches Pathologies Infectieuses IFR 66   (France)

^c INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORESCENT DYE; OLIGODEOXYNUCLEOTIDE DERIVATIVE;

ARTICLE; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG UPTAKE; GENE TARGETING; HELA CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; VIRUS PARTICLE;

CELL LINE; FLOW CYTOMETRY; FLUORESCENT DYES; HELA CELLS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MICROSCOPY, CONFOCAL; OLIGONUCLEOTIDES; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34547143223     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2006.0061     Document Type: Article

References (39)

1. ANDREOLA, M.L., PILEUR, F., CALMELS, C., VENTURA, M., TARRAGO-LITVAK, L., TOULMÉ, J.J., and LITVAK, S. (2001). DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 40, 10087-10094.
2. BENNETT, C.F., CHIANG, M.-Y., CHAN, H., SHOEMAKER, J.E.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
3. BOULME, F., FREUND, F., GRYAZNOV, S., NIELSEN, P.E., TARRAGO-LITVAK, L., and LITVAK, S. (2000). Study of HIV-2 primer-template initiation complex using antisense oligonucleotides. Eur. J. Biochem. 267, 2803-2811.
4. BRAUN, H., BOLLER, K., LOWER, J., BERTLING, W.M., and ZIMMER, A. (1999). Oligonucleotide and plasmid DNA packaging into polyoma VP1 virus-like particles expressed in Escherichia coli. Biotechnol. Appl. Biochem. 29, 31-43.
5. CAMPBELL, S., and VOGT, V.M. (1995). Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1. J. Virol. 69, 487-497.
6. CHARNEAU, P., MIRAMBEAU, G., ROUX, P., PAULOUS, S., BUC, H., and CLAVEL, F. (1994). HIV-1 reverse transcription. A termination step at the center of the genome. J. Mol. Biol. 241, 651-662.
7. DE SOULTRAIT, V.R., LOZACH, P.Y., ALTMEYER, R., TARRAGO-LITVAK, L., LITVAK, S., and ANDREOLA. M.L. (2002). DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti- integrase agents. J. Mol. Biol. 324, 195-203.
8. EHRLICH, L.S., LIU, T., SCARLATA, S., CHU, B., and CARTER, C.A. (2001). HIV-1 capsid protein forms spherical (immature-like) and tubular (mature-like) particles in vitro: structure switching by pH-induced conformational changes. Biophys. J. 81, 586-594.
9. FREUND, F., BOULME, F., MICHEL, J., VENTURA, M., MOREAU, S., and LITVAK, S. (2001). Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex. Antisense Nucleic Acid Drug Dev. 11, 301-315.
10. GAIT, M.J. (2003). Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues Cell. Mol. Life Sci. 60, 1-10.
11. GALDERISI, U., CASCINO, A., and GIORDANO A. (1999). Antisense oligonucleotides as therapeutic agents. J. Cell Physiol. 181, 251-257.
12. GARCIA-CHAUMONT, C., SEKSEK, O., GRZYBOWSKA, J., BOROWSKI, E., and BOLARD, J. (2000). Delivery systems for antisense oligonucleotides. Pharmacol. Ther. 87, 255-277.
13. GOLDMAN, C., PETRY, H., FRYE, S., AST, O., EBITSCH, S., JENTSCH, K.D., HAUP, F.J., WEBER, F., TREBST, C., NISSLEIN, T., HUNSMANN, G., WEBER, T., and LÜKE, W. (1999). Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies. J. Virol. 73, 4465-4469.
14. HELD, D.M., KISSEL, J.D., PATTERSON, J.T., NICKENS, D.G., and BURKE, D.H. (2006). HIV-1 inactivation by nucleic acid aptamers. Front. Biosci. 1, 89-112.
15. JING, N., and HOGAN, M.E. (1998). Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J. Biol. Chem, 273, 34992-34999.
16. JING, N., and XU, X. (2001). Rational drug design of DNA oligonucleotides as HIV inhibitors. Curr. Drug Targets Infect. Disord. 1, 79-90.
17. JING, N., MARCHAND, C., GUAN, Y., LIU, J., PALLANSCH, L., LACKMAN-SMITH, C., DE CLERCQ, E., and POMMIER, Y. (2001). Structure-activity of inhibition of HIV-1 integrase and virus replication by G-quartet oligonucleotides. DNA Cell Biol. 20, 499-508.
18. JOHNSON, A.A., MARCHAND, C., and POMMIER, Y. (2004). HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trials. Curr. Top. Med. Chem. 4, 1059-1077.
19. KANEDA, Y. (2003). New vector innovation for drug delivery, development of fusigenic non-viral particles. Curr. Drug Targets 4, 599-602.
20. KANEDA, Y., NAKAJIMA, T., NISHIKAWA, T., YAMAMOTO, S., IKEGAMI, H., SUZUKI, N., NAKAMURA, H., MORISHITA, R., and KOTANI, H. (2002). Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol. Ther. 6, 219-226.
21. KANEDA, Y., YAMAMOTO, S., and NAKAJIMA, T. (2005). Development of HVJ envelope vector and its application to gene therapy. Adv. Genet. 53, 307-332
22. MAZUMDER, A., NEAMATI, N., OJWANG, J.O., SUNDER, S., RANDO, R.F., and POMMIER, Y. (1996). Inhibition of the HIV-1 integrase by guanosine quartet structures. Biochemistry 35, 13762-13771.
23. METIFIOT, M., LEON, O., TARRAGO-LITVAK, L., LITVAK, S., and ANDREOLA, M.L. (2005). Targeting HIV-1 integrase with aptamers selected against the purified RNase H domain of HIV-1 reverse transcriptase. Biochimie 87, 911-919.
24. NIMJEE, S.M., RUSCONI, C.P., and SULLENGER, B.A. (2005). Aptamers: an emerging class of therapeutics. Annu. Rev. Med. 56, 555-583.
25. OEHLKE, J., BIRTH, P., KLAUSCHENZ, E., WIESNER, B., BEYERMANN, M., OKSCHE, A., and BIENERT, M. (2002). Cellular uptake of antisense oligonucleotides after complexing or conjugation with cell-penetrating model peptides. Eur. J. Biochem. 269, 4025-4032.
26. OJWANG, J., ELBAGGARI, A., MARSHALL, H.B., JAYARAMAN, K., MCGRATH, M.S., and RANDO, R.F. (1994) Inhibition of HIV-1 activity in vitro by oligonucleotides composed entirely of guanosine and thymidine. J. Acquir. Immune Defic. Syndr. 7, 560-570.
27. OKIMOTO, T., FRIEDMANN, T., and MIYANOHARA, A. (2001). VSV-G envelope glycoprotein forms complexes with plasmid DNA and MLV retrovirus-like particles in cell-free conditions and enhances DNA transfection. Mol. Ther. 4, 232-238.
28. PARISSI, V., CAUMONT, A.B., DE SOULTRAIT, V.R., CALMELS, C., PICHUANTES, S., LITVAK, S., and DUPONT, C.H. (2000). Selection of amino acid substitutions restoring activity of HIV-1 integrase mutated in its catalytic site using the yeast Saccharomyces cerevisiae. J. Mol. Biol. 295, 755-765.
29. PHAN, A.T., KURYAVYI, V., MA, J.B., FAURE, A., ANDREOLA, M.L., and PATEL, D.J. (2005). An interlocked dimeric parallel-stranded DNA quadruplex: a potent inhibitor of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 102, 634-639.
30. RICHARD, E., MENDEZ, M., MAZURIER, F., MOREL, C., COSTET, P., XIA, P., FONTANELLAS, A., GERONIMI, F., CARIO-ANDRE, M., TAINE, L., GED, C., MALIK, P., DE VERNEUIL, H., and MOREAU-GAUDRY, F. (2001). Gene therapy of a mouse model of protoporphyria with a self-inactivating erythroid-specific lentiviral vector without preselection. Mol. Ther. 4, 331-338.
31. ROCANCOURT, D., BONNEROT, C., JOUIN, H., EMERMAN, M., and NICOLAS, J.F. (1990). Activation of a beta-galactosidase recombinant provirus: application to titration of HIV and HIV-infected cells. J. Virol. 64, 2660-2668.
32. SCHUBERT, S., and KURRECK, J. (2006). Oligonucleotide-based antiviral strategies. Handb. Exp. Pharmacol. 173, 261-287.
33. SCHULTZE, P., MACAYA, R.F., and FEIGON, J. (1994). Three-dimensional solution structure of the thrombin-binding DNA aptamer d (GGTTGGTGTGGTTGG). J. Mol. Biol. 235, 1532-1547.
34. SEN, D., and GILBERT, W. (1990). A sodium-potassium switch in the formation of four-stranded G4-DNA. Nature 344, 410-414.
35. SMITH, C.C., AURELIAN, L., REDDY, M.P., MILLER, P.S., and TS'O, P.O. (1986). Antiviral effect of an oligo(nucleoside methylphosphonate) complementary to the splice junction of herpes simplex virus type 1 immediate early premRNAs 4 and 5. Proc. Natl. Acad. Sci. USA 83, 2787-2791.
36. STRITZKER, J., and GOEBEL, W. (2004). Listeria monocytogenes infection-dependent transfer of exogenously added DNA to fibroblast COS-1 cells. Mol. Genet. Genomics 272, 497-503.
37. THIERRY, A.R., VIVÈS, E., RICHARD, J.-P., PREVOT, P., MARTINAND-MARI, C., ROBBINS, I., and LEBLEU, B. (2003). Cellular uptake and intracellular fate of antisense oligonucleotides Curr. Opin. Mol. Ther. 5, 133-138.
38. VENTURA, M., TARRAGO-LITVAK, L., DOLLÉ, V., NGUYEN, C.H., LEGRAVEREND, M., FLEURY, H.J.A., and LITVAK, S. (1999). Effect of nucleoside analogs and non-nucleoside inhibitors of HIV-1 reverse transcriptase on cell-free virions. Arch. Virol. 144, 513-523.
39. WIZNEROWICZ, M., and TRONO, D. (2005). Harnessing HIV for therapy, basic research and biotechnology. Trends Biotechnol. 23, 42-47.